Shares in Novo Nordisk (NOVOb.CO) rose as much as 5 percent on Monday after the U.S. Food and Drug Administration (FDA) approved the diabetes drug Tresiba, allowing the Danish drugmaker to prepare its largest ever drug launch. The FDA’s decision late on Friday came two years after it had rejected the long-acting form of […]
STOCKHOLM – Novo Nordisk (NVO) reported today that its type 2 diabetes treatment Victoza in combination with metformin, proved superior in reducing HbA1c than Sanofi’s lixisenatide in combination with metformin. Novo’s stock jumped slightly this morning to a price of $56.37, up from its opening $55.94 per share. In the head-to-head trial, which surveyed […]
Analysts are confident the U.S. Food and Drug Administration (FDA) will soon approve Novo Nordisk’s new long-lasting insulin drug Tresiba — just as they were before the drug was first rebuffed two years ago. Tresiba is considered as a future blockbuster for the Danish company, the Nordic region’s most valuable, but the U.S. regulator asked […]
Humira during 2014 remained the world’s best-selling prescription medicine; Sovaldi vaulted into second place in its first full year on the market; Harvoni is challenging Humira for the 2015 sales crown.
A joint North Carolina State University and University of North Carolina research project aims to replace insulin injections with an insulin patch. Dr. Zhen Gu, a professor at the schools’ Joint Department of Biomedical Engineering, says the work aims to make administering insulin autonomous for patients. “Basically we developed this kind of so-called smart insulin […]